1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Cytomegalovirus (CMV) Infections- Market Insights, Epidemiology, and Market Forecast-2028

Cytomegalovirus (CMV) Infections- Market Insights, Epidemiology, and Market Forecast-2028

  • September 2019
  • 275 pages
  • ID: 5816562
  • Format: PDF
  • By Delve Insight

Summary

Table of Contents

‘Cytomegalovirus (CMV) Infections- Market Insights, Epidemiology, and Market Forecast-2028’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Cytomegalovirus (CMV) Infections in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
CMV affects young children mainly, but it is estimated that by age 30 in the United States, half of all adults are, or have been, infected. The virus can pass from an infected, pregnant mother to her child through the shared blood supply (umbilical cord).
Among healthy individuals, CMV infection usually causes no symptoms; however, when CMV is transmitted congenitally (congenital CMV or cCMV) it can cause severe sequel. Despite the relatively high prevalence of cCMV infections and potentially serious effects, many women are unfamiliar with the risk of cCMV.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2028

Cytomegalovirus (CMV) Infections - Disease Understanding and Treatment Algorithm

Cytomegalovirus (CMV) is a commonly acquired infection and a member of the Herpesviridae family. Cytomegalovirus infection (CMV) is a viral infection that rarely causes obvious illness. There are three main types of CMV infections: acquired, recurring, or congenital. When the infection develops for the first time it is called acquired CMV. Recurrent CMV infection is defined as a new CMV infection in a patient with previous evidence of CMV infection in whom the virus has not been detected for at least 4 weeks during active surveillance. If a pregnant woman has an active CMV infection, the virus can be passed to the unborn baby and when it affects a baby in the womb, it’s known as congenital CMV.

The primary infection manifests as an asymptomatic or self-limited febrile illness in immuno-competent individuals, after which CMV establishes life-long latency in various cells which serve as reservoirs for reactivation and as carriers of infection to susceptible individuals. There are certain groups at high risk for serious complications from CMV infection which includes: Pregnant Women, Transplant Patients with compromised immune systems, Patients with HIV, and Very low birth weight and premature infants. Cytomegalovirus (CMV) Infections Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total seroprevalence of CMV in 7MM, Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in 7MM, Number of Infants born with Congenital CMV in 7MM, CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in 7MM, Number of CMV Patients among Solid Organ Transplants (SOT) in 7MM, Number of Refractory CMV Patients after HSCT/SOT in 7MM and CMV Retinitis among HIV Patients in 7MM) scenario of Cytomegalovirus (CMV) Infections in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028.
According to the analyst, the total diagnosed cases of CMV were found out to be approximately 110,540 in the 7MM. The number of CMV cases in the 7MM is expected to increase during the study period of 2017–2028. In 7MM, Hematopoietic Stem Cell Transplants (allogeneic HSCT) patients is increasing throughout the study period (2017-2028). While, HIV patients is decreasing throughout the study period (2017-2018) due to the High Active Antiretroviral Therapy (HAART).
Cytomegalovirus (CMV) Infections Drug Chapters
This segment of the Cytomegalovirus (CMV) Infections report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. Currently, antiviral drugs are used for CMV infection following transplant procedures. The drugs include valganciclovir, ganciclovir, cidofovir, foscarnet, or a combination, etc. Recently, Prevymis (Letermovir) received FDA approval for the prevention of Human Cytomegalovirus (HCMV) infection in transplant patients.
There are two major strategies for CMV disease prevention after liver transplantation that includes preemptive therapy and antiviral prophylaxis. Before ART was widely available, daily use of oral ganciclovir (no longer marketed in the United States) for primary prophylaxis significantly reduced the incidence of CMV disease in a randomized, placebo-controlled trial.
The first-line options for therapy of CMV disease, are almost always intravenous ganciclovir or oral valganciclovir. Foscavir (FOS) is considered second-line therapy but is the preferred drug for patients who are failing GCV therapy due to viral resistance, or those who cannot be treated with GCV due to dose-limiting neutropenia or leucopenia. Another second-line therapy for CMV disease, cidofovir (Vistide, Gilead), is—like foscarnet—an inhibitor of the CMV DNA polymerase.
CMV Infection market is flooded with Generic products as the top-selling drugs have gone off-patent. Most recent gone off the patent drug was Valcyte, which lost its patent in 2013 and 2015 in the US and Europe, respectively.

Cytomegalovirus (CMV) Infections Market Outlook

According to the analyst, the market of Cytomegalovirus (CMV) Infections in 7MM was found to be approximately USD 1195.10 million in 2017. Cytomegalovirus (CMV) Infections market size in the United States accounted for approx. 68.16% of the total market in 2017.
Among the EU5 countries, in 2017, France had the highest market size with approximately USD 84.00 million, while Italy had the lowest market size for CMV Infection with approximately USD 47.00 million.
The market size of prophylactic & therapeutic CMV Infection in seven major markets was approximately USD 771.00 million & 423.00 million in 2017.

Cytomegalovirus (CMV) Infections Drugs Uptake
The dynamics of Cytomegalovirus Infection market is anticipated to change during the forecasted period owing to the expected launch of emerging therapies. There are many pipeline therapies under development for the prevention of Congenital Cytomegalovirus and treatment of Cytomegalovirus infection following transplant (allogeneic hematopoietic stem cell transplantation/Solid-organ transplantation). The therapies which are under development for the prophylaxis or treatment of CMV Infection are Maribavir (Shire), ATA230 (Atara Biotherapeutics), Viralym-M (ViraCyte), V160 (Merck Sharp & Dohme Corp), Cytotect-70 (BioTest, (EU5 only)) and Triplex (Helocyte).

Cytomegalovirus (CMV) Infections Report Insights

• Patient Population by Total diagnosed cases
• Infants born with Congenital CMV
• CMV Patients among Hematopoietic Stem Cell Transplants (HSCT)
• CMV Patients among Solid Organ Transplants (SOT)
• Refractory CMV Patients after HSCT/SOT
• CMV Retinitis among HIV Patients
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Cytomegalovirus (CMV) Infections Report Key Strengths

• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Cytomegalovirus (CMV) Infections Report Assessment

• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits

• This report will help to develop Business Strategies by understanding the trends shaping and driving Cytomegalovirus (CMV) Infections market
• Organize sales and marketing efforts by identifying the best opportunities for Cytomegalovirus (CMV) Infections market
• To understand the future market competition in the Cytomegalovirus (CMV) Infections market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off

($6250)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Pediatric Vaccines Market - Growth, Trends, and Forecast (2019 - 2024)

Pediatric Vaccines Market - Growth, Trends, and Forecast (2019 - 2024)

  • $ 4250
  • October 2019

Market OverviewThe global pediatric vaccine market is expected to register 11.7% CAGR during the forecast period 2019-2024. The growth of the pediatric vaccines market is attributed due to the rising burden ...

Plague - Pipeline Review, H2 2019

Plague - Pipeline Review, H2 2019

  • $ 2000
  • September 2019

Plague - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Plague - Pipeline Review, H2 2019, provides an overview of the Plague (Infectious Disease) pipeline ...

Germany Automated Microbiology Market for over 100 Tests

Germany Automated Microbiology Market for over 100 Tests

  • $ 3750
  • September 2019

Germany Automated Microbiology Market for over 100 Tests: Supplier Shares and Strategies, Volume and Sales Forecasts for 100 Molecular, Identification, Susceptibility, Blood Culture, Urine Screening and ...


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on